Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

985 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A clinical survey of dehydration during winter training in elite fencing athletes.
Eda N, Azuma Y, Takemura A, Saito T, Nakamura M, Akazawa N, Yamamoto M, Naito T, Kasai N, Shimizu K, Aoki Y, Hoshikawa M. Eda N, et al. Among authors: azuma y. J Sports Med Phys Fitness. 2022 Nov;62(11):1534-1540. doi: 10.23736/S0022-4707.21.13288-8. Epub 2021 Dec 16. J Sports Med Phys Fitness. 2022. PMID: 34913628
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T. Mikami H, et al. Among authors: azuma y. Cancer Immunol Res. 2024 Apr 1:OF1-OF12. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38563577
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer.
Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, Nagano H, Asanuma K, Kayukawa Y, Tsunenari T, Kamikawaji S, Iwabuchi R, Shinozuka J, Yamazaki M, Kuroi H, Ho SSW, Gan SW, Chichili P, Pang CL, Yeo CY, Shimizu S, Hironiwa N, Kinoshita Y, Shimizu Y, Sakamoto A, Muraoka M, Takahashi N, Kawa T, Shiraiwa H, Mimoto F, Kashima K, Kamata-Sakurai M, Ishikawa S, Aburatani H, Kitazawa T, Igawa T. Mikami H, et al. Among authors: azuma y. Cancer Immunol Res. 2024 Mar 20. doi: 10.1158/2326-6066.CIR-23-0638. Online ahead of print. Cancer Immunol Res. 2024. PMID: 38558120
Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes.
Núñez-Carpintero I, Rigau M, Bosio M, O'Connor E, Spendiff S, Azuma Y, Topf A, Thompson R, 't Hoen PAC, Chamova T, Tournev I, Guergueltcheva V, Laurie S, Beltran S, Capella-Gutiérrez S, Cirillo D, Lochmüller H, Valencia A. Núñez-Carpintero I, et al. Among authors: azuma y. Nat Commun. 2024 Feb 28;15(1):1227. doi: 10.1038/s41467-024-45099-0. Nat Commun. 2024. PMID: 38418480 Free PMC article.
985 results